Compare BIIB & EIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIIB | EIX |
|---|---|---|
| Founded | 1978 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3B | 27.8B |
| IPO Year | 1996 | 1994 |
| Metric | BIIB | EIX |
|---|---|---|
| Price | $196.24 | $71.56 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 25 | 13 |
| Target Price | ★ $206.83 | $72.09 |
| AVG Volume (30 Days) | 849.0K | ★ 2.0M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 5.17% |
| EPS Growth | N/A | ★ 248.94 |
| EPS | ★ 2.15 | 1.37 |
| Revenue | $9,890,600,000.00 | ★ $19,317,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.17 |
| P/E Ratio | $91.56 | ★ $52.34 |
| Revenue Growth | 2.22 | ★ 9.76 |
| 52 Week Low | $121.06 | $49.25 |
| 52 Week High | $205.97 | $76.22 |
| Indicator | BIIB | EIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 53.18 |
| Support Level | $184.00 | $68.62 |
| Resistance Level | $199.40 | $71.90 |
| Average True Range (ATR) | 6.03 | 1.46 |
| MACD | -0.10 | 0.02 |
| Stochastic Oscillator | 62.96 | 61.04 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.